<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Trials</title>
    <link rel="stylesheet" href="style.css" type="text/css">
</head>

<body>
    <header class="top-content">
        <div class="header head-item">Hepion Pharmaceuticals (NASDAQ:HEPA)</div>
        <div class="nav head-item">
            <div class="nav-item"><a href="index.html">Summary</a></div>
            <div class="nav-item"><a href="factsheet.html">Fact Sheet</a></div>
            <div class="nav-item"><a href="trial.html" class="location">Trials</a></div>
        </div>
    </header>

    <section class="preview">
        <div class="preview-item preview-left">"TACKLING CHRONIC LIVER DISEASE:<br>NASH, Hepatitis, Cirrhosis, Liver
            Failure, and Cancer."</div>
        <div class="preview-item preview-right">"Hepion Pharmaceuticals is a clinical stage biopharmaceutical company
            focused on Artificial Intelligence driven therapeutic drug development for the treatment of non-alcoholic
            steatohepatitis, fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases."</div>
    </section>
    <h1 class="watermark">Caprice Yuri</h1>

    <section class="img">
        <img src="image/cycleA.gif" alt="Cyclophilin A">
        <img src="image/cycleB.gif" alt="Cyclophilin B">
        <img src="image/cycleD.gif" alt="Cyclophilin D">
    </section>

    <section class="trial-main">
        <br><h1>Pre-Clinical & Clinical Trials</h1><br>

        <br><div class="trial-point-header trial-style">P2B ASCEND - NASH</div>
        <div class="trial-status trial-style">Status: In-Progress</div>
        <div class="trial-point-content trial-style"><br>Summary: Evaluate the safety, tolerability, and efficacy of Rencofilstat in adult patients with NASH and Advanced Liver Fibrosis.<br><br>Details: Enrollment of 336 pacticipants, each cohort consists of 84 patients with biopsy proven NASH F2/F3. Patients will be dose in a 1:1:1:1 ratio between Rencofilstat 75mg, 150mg, 225mg, and matching placebo. The duration of dosing will be 1 year with 1 month observation and follow up period.<br><br>Endpoints: Efficacy, superiority of Rencofilstat compared to placebo and assessing the proportion of patients with improvement in fibrosis OR NASH resolution without worsening of fibrosis.</div><br>

        <br><div class="trial-point-header trial-style">P2 ALTITUDE - NASH</div>
        <div class="trial-status trial-style">Status: In-Progress</div>
        <div class="trial-status trial-style" id="partner">Collaboration: HepQuant</div>
        <div class="trial-point-content trial-style"><br>Summary: Evaluate the safety, tolerability, and efficacy of Rencofilstat in adult patients with NASH F3.<br><br>Details: Enrollment of 60 participants, each cohort consists of 20 patients classified as NASH F2/F3 based on either historical biopsy or by using AGILE 3+ criteria. Patients will be dose in a 1:1:1 ratio between Rencofilstat 75mg, 150mg, and 225mg. The duration of dosing will be 120 days with follow up period of 14 days.<br>The study will use HepQuant's SHUNT test, which provides sensitive measurement of hepatic function and detailed information on the role Rencofilstat plays in liver health in NASH patients with advance fibrosis. The SHUNT test will be performed at days 1, 60, and 120.<br><br>Endpoints: Efficacy - HepQuant SHUNT, Safety, Tolerability, and Pharmacokinetics.</div>

    </section>
</body>

</html>